Table 3.
Data on hospital admission, treatments administered, and mortality among the groups analyzed
| Total (N = 163) | High viral load, Ct < 30 (N = 96) | Low viral load, Ct => 30 (N = 67) | P-value | |
|---|---|---|---|---|
| Clinical management, n (%) | ||||
| Admission to hospital | 141 (86.5) | 85 (88.5) | 56 (83.6) | 0.362 |
| Admission to ICU | 31 (19) | 15 (15.6) | 16 (23.9) | 0.186 |
| Days in ICU | 10 (0–33) | 10.5 (0–35) | 7 (0–25) | 0.654 |
| Mechanic ventilation | 26 (16) | 13 (13.5) | 13 (19.4) | 0.315 |
| Acute myocardial infarction type 2 | 15 (9.2) | 6 (6.3) | 9 (13.4) | 0.199 |
| Treatment, n (%) | ||||
| Antibiotics* | 123 (75.9) | 74 (77.9) | 49 (73.1) | 0.485 |
| Hydroxychloroquine | 104 (64.6) | 58 (61.7) | 46 (68.7) | 0.363 |
| Lopinavir/ritonavir | 80 (50) | 47 (50) | 33 (50) | 1 |
| Azithromycin | 57 (35.8) | 26 (28.3) | 31 (46.3) | 0.019 |
| Corticosteroids | 14 (8.7) | 11 (11.7) | 3 (4.5) | 0.109 |
| Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker | 20 (15.2) | 11 (14.5) | 9 (16.1) | 0.808 |
| Mortality, n (%) | ||||
| In-hospital mortality | 30 (18.4) | 23 (24) | 7 (10.4) | 0.029 |
Ct = cycle threshold; ICU = intensive care unit.
*
Azithromycin not included.